Abstract 2303P
Background
The interpretation of gene variants from NGS data may support clinical and treatment decisions in pleural mesothelioma. Predicting how a variant can affect the functions of the protein- or disease-relevant pathways is challenging and, so far, it largely relies on gene-centric algorithms. We complement this by integrating a protein-centric interpretation of the variants in order to expand the functional information accessible from clinical NGS.
Methods
We have screened for pleural mesothelioma clinical NGS datasets accessible from literature reports focusing on the relevant genes BAP1 and NF2. NGS results are combined with protein information from neXtProt using an in-house developed program. Conservation-based predictions are integrated with structural and functional protein information to assess the functional impact of the variants. The pleural mesothelioma molecular pathway in the WikiPathways knowledgebase permits us to interpret the relevance of the variant within its pathway environment (https://www.wikipathways.org/pathways/WP5087.html).
Results
The variants from an initial NGS dataset have been mapped on the protein sequences, resulting in 209 protein variants for BAP1 and 181 for NF2 isoform 1. Functional predictions from the algorithms SIFT and PolyPhen-2 embedded in neXtProt presented approx. 60% agreement for BAP1 and 51% for NF2. 13% of the BAP1 and 22% of the NF2 variants had no prediction. The integration of the protein-centric information refined the functional interpretation of 121 variants in BAP1 and 107 in NF2 located in regions critical for the function of the proteins, like interacting or enzymatically active domains, FERM domains or loci of post-translational modifications. Among them, 67 variants with missing or ambiguous prediction between SIFT and PolyPhen-2 (30 in BAP1, 37 in NF2). The molecular pathways of pleural mesothelioma revealed critical sites in the BAP1 and NF2 pathways potentially affected by the variants (WikiPathways:WP5087; Malignant pleural mesothelioma (WP5087)).
Conclusions
Protein-centric and pathway-embedded interpretation of gene variants may complement NGS information for clinical decisions in pleural mesothelioma.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
The Marlies Schwegler Foundation.
Disclosure
F.W.F. Cerciello: Financial Interests, Institutional, Advisory Board: Bristol Myers Squibb, PharmaMar. All other authors have declared no conflicts of interest.
Resources from the same session
2273P - Influence of body mass index (BMI) on the response to chemotherapy in patients with HER2+ breast cancer: Role of the leptin axis
Presenter: Marta González Rodríguez
Session: Poster session 08
2274P - Deep learning-based prediction of pathologic complete response to neoadjuvant therapy in breast cancer using H&E images and RNA-Seq in the IMMUcan study
Presenter: Christian Esposito
Session: Poster session 08
2275P - Circulating leptin and adiponectin levels in premenopausal women with and without breast cancer (BC) and a body mass index (BMI) ≥25 kg/m2
Presenter: Isabel Calvo
Session: Poster session 08
2276P - Regulation of major histocompatibility class-I gene methylation using DNA methyltransferase inhibitor and PD-L1 inhibitor in triple-negative breast cancer
Presenter: Young Ju Jeong
Session: Poster session 08
2277P - A colorimetric biosensor to track Trop-2 status of tumor cells for diagnosis of breast cancer
Presenter: Tianyu Zeng
Session: Poster session 08
2278P - Endothelial cell heterogeneity defined by single-cell spatial transcriptomic analysis of breast cancers
Presenter: Krisztian Homicsko
Session: Poster session 08
2279P - Glucocorticoid receptor antagonism and beta adrenergic receptor inhibition: Implications in triple-negative breast cancer brain metastasis
Presenter: Andra Antohi
Session: Poster session 08
2280P - MiR-193a-3p: A pan-repressor of H2S synthesizing enzymes regulates tumorigenesis and immunosurveillance in breast cancer
Presenter: Alyaa Dawoud
Session: Poster session 08
2281P - Multi-omics evaluation of TFE3-fusions and potential association with immuno-metabolic vulnerabilities in alveolar soft part sarcoma (ASPS) and translocation-positive renal cell carcinoma (tRCC)
Presenter: Shuanzeng Wei
Session: Poster session 08
2282P - Tissue glycan profiling in predicting immunotherapy response in renal cell carcinoma and hepatocelllular carcinoma
Presenter: Qin Jian Low
Session: Poster session 08